As providers and payers exert ever greater pressure on the pharma industry, will they force manufacturers to offer significant pricing concessions and will this become the new normal for the US healthcare system? Brett Gardiner reports.
George Forsyth
Advertisement
George Forsyth is Associate Consultant, Market Access, Research Partnership.
Articles by George Forsyth
Advertisement
Latest Updated Articles
How Will COVID-19 Affect the Financing of Healthcare Provision Across the US?Published: June 29th 2020 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
2
FDA Approves Breyanzi for Adults with Relapsed or Refractory Marginal Zone Lymphoma
3
Pharmaceutical Executive Daily: FDA Names Tracy Beth Høeg as Acting Director of CDER
4
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
5
